According to the Yipinhong announcement, its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for benzbromarone tablets approved and issued by the State Drug Administration. The specification is 50 mg, and the approval number is valid until July 20, 2031. This drug is used for essential hyperuricemia and intermittent periods of gout arthritis. It is a National Health Insurance Class B product and a national base drug, and is considered to have passed the consistency evaluation. In 2025, its sales scale in some domestic public hospitals was about 269 million yuan. This approval helps enhance the company's core competitiveness, but there is a risk that drug sales will fall short of expectations.

According to the Yipinhong announcement, its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for benzbromarone tablets approved and issued by the State Drug Administration. The specification is 50 mg, and the approval number is valid until July 20, 2031. This drug is used for essential hyperuricemia and intermittent periods of gout arthritis. It is a National Health Insurance Class B product and a national base drug, and is considered to have passed the consistency evaluation. In 2025, its sales scale in some domestic public hospitals was about 269 million yuan. This approval helps enhance the company's core competitiveness, but there is a risk that drug sales will fall short of expectations.